{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:01:48Z","timestamp":1778144508784,"version":"3.51.4"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Valproic acid (VPA) is widely used as an antiepileptic drug in children, and it is usually coadministered with other antiepileptic drugs. Because of its narrow therapeutic range and large variations in pharmacokinetic\/pharmacodynamic behavior in different individuals, therapeutic drug monitoring of the trough total VPA concentration is commonly used to guide dosing. However, as only the free fraction of VPA that exerts pharmacological and toxic effects, it may be more meaningful to determine the unbound VPA concentration in plasma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Free fraction of VPA in plasma was extracted by ultrafiltration. Ultra high performance liquid chromatography coupled with mass spectroscopy was used to measure VPA in the negative ionization mode. This method was validated by studies of its selectivity, linearity, lower limit of quantification, accuracy, precision, recovery, matrix effect, and stability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The method was validated over a linear range of 0.2\u201325 mcg\/mL, and its lower limit of quantification was 0.2 mcg\/mL. The method's relative standard deviations for intra- and inter-day precision were &lt;15%, and its accuracy (relative error) was \u00b13.22%. The recoveries and matrix effect of unbound VPA at 3 different concentrations satisfied our requirements for the analysis of biological samples, and no significant degradation of VPA was observed under different storage conditions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Simple ultra high performance liquid chromatography coupled with mass spectroscopy showed good performance when used to measure unbound VPA concentration, this method may be used to study the relationship between unbound VPA concentrations and its effectiveness by the use of therapeutic drug monitoring.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000431","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T15:05:43Z","timestamp":1499785543000},"page":"575-579","source":"Crossref","is-referenced-by-count":11,"title":["Development of a Simple and Rapid Method to Measure Free Fraction of Valproic Acid in Plasma Using Ultrafiltration and Ultra High Performance Liquid Chromatography\u2013Mass Spectroscopy: Application to Therapeutic Drug Monitoring"],"prefix":"10.1097","volume":"39","author":[{"given":"Shansen","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2146\/ajhp140191","article-title":"Comparison of free fraction serum valproic acid concentrations between inpatients and outpatients","volume":"72","author":"Gibbs","year":"2015","journal-title":"Am J Health Syst Pharm."},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.yebeh.2005.04.010","article-title":"The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview","volume":"7","author":"Ferraro","year":"2005","journal-title":"Epilepsy Behav."},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","article-title":"Clinical pharmacokinetics of valproic acid","volume":"15","author":"Zaccara","year":"1988","journal-title":"Clin Pharmacokinet."},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2125.1983.tb02179.x","article-title":"Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing","volume":"16","author":"Rapeport","year":"1983","journal-title":"Br J Clin Pharmacol."},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1248\/bpb.35.971","article-title":"Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy","volume":"35","author":"Itoh","year":"2012","journal-title":"Biol Pharm Bull."},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.2042-7158.2011.01282.x","article-title":"No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy","volume":"63","author":"Suzuki","year":"2011","journal-title":"J Pharm Pharmacol."},{"key":"R7-20230928","first-page":"361","article-title":"The influence of plasma albumin concentration on the analysis methodology of free valproic acid by ultrafiltration and its application to therapeutic drug monitoring","volume":"15","author":"Zhang","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.seizure.2014.10.010","article-title":"Correlation of saliva and serum free valproic acid concentrations in persons with epilepsy","volume":"25","author":"Dwivedi","year":"2015","journal-title":"Seizure."},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00007691-198503000-00020","article-title":"Determination of free valproic acid concentrations using the Amicon Micropartition MPS1 ultrafiltration system","volume":"7","author":"March","year":"1985","journal-title":"Ther Drug Monit."},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jchromb.2011.05.022","article-title":"LC-MS\/MS method for simultaneous determination of valproic acid and major metabolites in human plasma","volume":"879","author":"Gao","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/FTD.0000000000000256","article-title":"Development and validation of a simple and rapid UPLC-MS assay for valproic acid and its Comparison with immunoassay and HPLC methods","volume":"38","author":"Zhao","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal Chem."},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00007691-198212000-00003","article-title":"Determination of unbound valproic acid concentration in plasma by equilibrium dialysis and gas\u2013liquid chromatography: methodological aspects and observations in epileptic patients","volume":"4","author":"Riva","year":"1982","journal-title":"Ther Drug Monit."},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00007691-198306000-00007","article-title":"Diurnal fluctuations in free and total plasma concentrations of valproic acid at steady state in epileptic patients","volume":"5","author":"Riva","year":"1983","journal-title":"Ther Drug Monit."},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jchromb.2006.11.027","article-title":"Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS\/MS","volume":"850","author":"Cheng","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2710.2008.00885.x","article-title":"Characterization of non-linear relationship between total and unbound serum concentrations of valproic acid in epileptic children","volume":"33","author":"Ueshima","year":"2008","journal-title":"J Clin Pharm Ther."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201710000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T01:05:02Z","timestamp":1695863102000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201710000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000431","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}